United Therapeutics Corporation Reports Third Quarter 2020 Financial Results
The Pharma Data
OCTOBER 27, 2020
Food and Drug Administration (FDA) in support of an efficacy supplement to the Tyvaso new drug application (sNDA), which we expect to result in revised labeling reflecting the outcome of the INCREASE study. We submitted a 505(b)(1) new drug application (NDA) to the FDA for our Trevyent disposable treprostinil pump system in June 2019.
40 
Let's personalize your content